MB
DYN icon

MPM BioImpact’s Dyne Therapeutics DYN Stock Holding History

MPM BioImpact’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.7M Buy
1,922,093
+513,941
+36% +$9.56M 2.6% 15
2026
Q1 		$25.5M Buy
1,408,152
+2,764
+0.2% +$47.7K 1.97% 21
2025
Q4 		$27.5M Sell
1,405,388
-40,973
-3% -$776K 3.15% 11
2025
Q3 		$18.3M Hold
1,446,361
– – 3% 13
2025
Q2 		$13.8M Buy
+1,446,361
New +$15.9M 2.39% 19

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

MPM BioImpact's DYN Position: Q2 2026 in Review

MPM BioImpact increased its Dyne Therapeutics (DYN) stake by 36% in Q2 2026, buying an estimated $9.56M and bringing the position to 1,922,093 shares worth $42.7M. The position accounts for 2.6% of the portfolio, ranked #15.

MPM BioImpact first reported a position in DYN in Q2 2025 and has held it in 5 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • MPM BioImpact held 1,922,093 shares of Dyne Therapeutics worth $42.7M as of Q2 2026.
  • MPM BioImpact bought 513,941 Dyne Therapeutics shares in Q2 2026, an estimated $9.56M.
  • Dyne Therapeutics made up 2.6% of MPM BioImpact's portfolio in Q2 2026, its #15 holding.
  • MPM BioImpact first reported a position in Dyne Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.